tert-butyl 4-(2-(ethoxycarbonyl)ethyl)benzylcarbamate | 383666-02-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tert-butyl 4-(2-(ethoxycarbonyl)ethyl)benzylcarbamate
• 英文别名: ethyl 3-[4-(N-tert-butoxycarbonylaminomethyl)phenyl]propionate；Ethyl 3-[4-(tert-butoxycarbonylaminomethyl)phenyl]propionate；ethyl 3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]propanoate
• CAS: 383666-02-2
• 化学式: C₁₇H₂₅NO₄
• 分子量: 307.39
• InChiKey: XVVXCZLVVRCZEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2-(ethoxycarbonyl)ethyl)benzylcarbamate 在 lithium aluminium tetrahydride 、 草酰氯 、 二甲基亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 tert-butyl 4-(2-formylethyl)benzylcarbamate
  参考文献：
  名称：

  鉴定KPNB1作为具有抗癌活性的氨基噻唑衍生物的细胞靶标

  摘要：

  我们发现氨基噻唑衍生物（E）-N-（5-苄基噻唑-2-基）-3-（呋喃-2-基）丙烯酰胺（1）具有很强的抗癌活性，并采取了蛋白质组学方法来鉴定化合物的目标蛋白1，输入蛋白β1（KPNB1）。使用荧光素标记的1进行的竞争性结合测定表明1具有对KPNB1的强结合亲和力（K d：〜20 n m）。此外，通过针对KPNB1，KPNA2，EGFR，ErbB2和STAT3的蛋白质印迹分析，我们确认了1对importin途径具有抑制作用。KPBN1似乎在几种癌细胞中过表达，并且siRNA诱导的KPNB1抑制作用显示出对癌细胞增殖的显着抑制作用，而使非癌细胞没有受到影响。因此，化合物1是开发KPNB1靶向抗癌药的有希望的新线索。荧光素标记的1可能是开发新型KPNB1抑制剂的有用定量探针。

  DOI：

  10.1002/cmdc.201600159
• 作为产物：
  描述：

  ethyl 3-[4-(tert-butoxycarbonylaminomethyl)phenyl]-2-propenoate 在 palladium-carbon 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以to obtain ethyl 3-[4-(tert-butoxycarbonylaminomethyl)phenyl]propionate (2.8 g, 9.11 mmol, 79%) as a colorless oil的产率得到tert-butyl 4-(2-(ethoxycarbonyl)ethyl)benzylcarbamate
  参考文献：
  名称：

  Benzoxazepinones and their use as squalene synthase inhibitors

  摘要：

  公开了一种化合物，其化学式表示为[I]：1，其中R1是可选择的1-羧基乙基基团，可选择的烷基-磺酰基团，可选择的（羧基-环烷基）-烷基基团，-X1-X2-Ar-X3-X4-COOH（其中X1和X4是键或烷基链，X2和X3是键，-O-，-S-，Ar是双价芳香族基等），R2是烷基，可选择地取代烷酰氧基和/或羟基，R3是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇和甘油三酯的活性，可用于预防和/或治疗高脂血症。

  公开号：

  US20030078251A1

文献信息

• NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1445250A1

  公开（公告）日：2004-08-11

  It is intended to provide a novel low-molecular weight amine derivative, that is absorbed well, has low toxicity, and has an excellent human β-tryptase inhibitory activity with extremely high selectivity, a pharmaceutically acceptable salt thereof, and a medicine containing the same as an active ingredient. The medicine of the present invention is efficacious as a prophylactic/therapeutic agent for diseases in the crisis and evolution of which are considered to be attributed to β-tryptase, for example, respiratory diseases, allergic diseases, inflammatory bowel diseases, hyperprolliferative skin diseases, vascular edema and rheumatoid arthritis.

  本发明旨在提供一种新型低分子量胺衍生物，该衍生物被很好地吸收，毒性低，并且具有极高选择性的优异人类β-色氨酸蛋白酶抑制活性，其药学上可接受的盐，以及含有该衍生物作为活性成分的药物。本发明的药物可作为一种预防/治疗剂，用于被认为是由β-色氨酸蛋白酶引起的危机和发展的疾病，例如呼吸道疾病、过敏性疾病、炎症性肠病、皮肤过度增生疾病、血管水肿和类风湿性关节炎。
• Synthesis and evaluation of 4-substituted benzylamine derivatives as β-tryptase inhibitors
  作者：Yutaka Miyazaki、Yutaka Kato、Tadashi Manabe、Hiroyasu Shimada、Masashi Mizuno、Takayuki Egusa、Munetaka Ohkouchi、Ikuya Shiromizu、Tomokazu Matsusue、Ichiro Yamamoto

  DOI：10.1016/j.bmcl.2006.02.064

  日期：2006.6

  Since P-tryptase is considered a critical mediator of asthma, potent tryptase inhibitors may be useful as new agents for the treatment of asthma. We investigated 4-substituted benzylamine derivatives and obtained M58539 (15h) as a potent inhibitor of beta-tryptase (IC50 = 5.0 nM) with high selectivity against other serine proteases, low molecular weight, clog P value less than 5, lack of amidino and guanidino groups, and independence of Zn2+ ion. (c) 2006 Elsevier Ltd. All rights reserved.
• BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1292585A1

  公开（公告）日：2003-03-19
• Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
  申请人：Kato Yutaka

  公开号：US20050043304A1

  公开（公告）日：2005-02-24

  It is intended to provide a novel low-molecular weight amine derivative, that is absorbed well, has low toxicity, and has an excellent human β-tryptase inhibitory activity with extremely high selectivity, a pharmaceutically acceptable salt thereof, and a medicine containing the same as an active ingredient. The medicine of the present invention is efficacious as a prophylactic/therapeutic agent for diseases in the crisis and evolution of which are considered to be attributed to β-tryptase, for example, respiratory diseases, allergic diseases, inflammatory bowel diseases, hyperprolliferative skin diseases, vascular edema and rheumatoid arthritis.
• [EN] BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS<br/>[FR] BENZOXAZEPINONES ET LEUR UTILISATION COMME INHIBITEURS DE LA SQUALENE SYNTHASE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2001098282A1

  公开（公告）日：2001-12-27

  There is disclosed a compound represented by formula (I), wherein R1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, -X?1-X2-Ar-X3-X4¿-COOH (wherein X?1 and X4¿ are a bond or alkylene group, X?2 and X3¿ are a bond, -O-, -S-, Ar is divalent aromatic group , etc.), R2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.